opipramol / Generic mfg. - LARVOL DELTA

Carbon Materials in Voltammetry: An Overview of Versatile Platforms for Antidepressant Drug Detection. (PubMed, Micromachines (Basel)) - "Moreover, the combination of voltammetric approaches with the unique characteristics of carbon and its derivatives has led to the development of powerful electrochemical sensing tools for detecting antidepressant drugs, which are highly desirable in healthcare, environmental monitoring, and the pharmaceutical industry. In this review, carbon-based materials, such as glassy carbon and boron-doped diamond, and a wide spectrum of carbon nanoparticles, including graphene, graphene oxides, reduced graphene oxides, single-walled carbon nanotubes, and multi-walled carbon nanotubes were described in terms of the sensing performance of agomelatine, alprazolam, amitriptyline, aripiprazole, carbamazepine, citalopram, clomipramine, clozapine, clonazepam, desipramine, desvenlafaxine, doxepin, duloxetine, flunitrazepam, fluoxetine, fluvoxamine, imipramine, nifedipine, olanzapine, opipramol, paroxetine, quetiapine, serotonin, sertraline, sulpiride, thioridazine, trazodone, venlafaxine,..."

Journal • Review • CNS Disorders • Depression • Mood Disorders • Personality Disorder • Psychiatry

Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - P=N/A | N=100 | Enrolling by invitation | Sponsor: Wroclaw Medical University | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Cardiovascular • CNS Disorders • Dental Disorders • Endocrine Disorders • Hypertension • Musculoskeletal Diseases • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Association of antidepressants with cataracts and glaucoma: a disproportionality analysis using the reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS) pharmacovigilance database. (PubMed, CNS Spectr) - "Most of the investigated antidepressants were associated with a lower risk of cataract reporting. TCAs, brexanolone, esketamine, and opipramol were associated with greater odds of cataract. For most antidepressants, there was an insignificant increase in reports of ACG and OAG."

Adverse events • Journal • Cataract • CNS Disorders • Depression • Glaucoma • Mood Disorders • Ophthalmology • Psychiatry

Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - P=N/A | N=100 | Enrolling by invitation | Sponsor: Wroclaw Medical University | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Cardiovascular • CNS Disorders • Dental Disorders • Endocrine Disorders • Hypertension • Musculoskeletal Diseases • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Implication of Rac1 GTPase in molecular and cellular mitochondrial functions. (PubMed, Life Sci) - "Inhibitors of Rac1 have been identified (NSC-23766, EHT-1864) and some are being developed for the treatment of cancer (MBQ-167) or central nervous system diseases (JK-50561). Their effects on mtRac1 warrant further investigations. An overview of mtRac1 is provided here."

Journal • Review • Oncology • BCL2 • RAC1

The anxiolytic drug opipramol inhibits insulin-induced lipogenesis in fat cells and insulin secretion in pancreatic islets. (PubMed, J Physiol Biochem) - "However, patients treated for depression or anxiety disorders by this tricyclic compound do not exhibit the body weight gain or the glucose tolerance alterations observed with various other antidepressant or antipsychotic agents such as amitriptyline and olanzapine, respectively...Similar inhibitory effects were observed in mouse and rat pancreatic islets and were reproduced with 100 μM haloperidol, in a manner that was independent from alpha2-adrenoceptor activation but sensitive to Ca release. All these results indicated that the anxiolytic drug opipramol is not only active in central nervous system but also in multiple peripheral tissues and endocrine organs. Due to its capacity to modulate the lipid and carbohydrate metabolisms, opipramol deserves further studies in order to explore its therapeutic potential for the treatment of obese and diabetic states."

Journal • CNS Disorders • Depression • Diabetes • Mood Disorders • Obesity • Psychiatry

Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - P=N/A | N=100 | Enrolling by invitation | Sponsor: Wroclaw Medical University | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Cardiovascular • CNS Disorders • Dental Disorders • Endocrine Disorders • Hypertension • Musculoskeletal Diseases • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - P=N/A | N=100 | Enrolling by invitation | Sponsor: Wroclaw Medical University | Trial completion date: Dec 2021 ➔ Dec 2022 | Trial primary completion date: Dec 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date • Cardiovascular • CNS Disorders • Dental Disorders • Endocrine Disorders • Hypertension • Musculoskeletal Diseases • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Novel Opipramol-Baclofen Combination Alleviates Depression and Craving and Facilitates Recovery From Substance Use Disorder-An Animal Model and a Human Study. (PubMed, Front Behav Neurosci) - "Our findings indicate a beneficial effect of O/B treatment. This study suggests a novel candidate for pharmacological treatment of patients with SUD and comorbid mood/anxiety disorders that may facilitate their rehabilitation."

Journal • Preclinical • CNS Disorders • Depression • Mood Disorders • Psychiatry

Tricyclic antidepressants versus 'active placebo', placebo or no intervention for adults with major depressive disorder: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. (PubMed, Syst Rev) - "Tricyclic antidepressants are recommended by clinical guidelines and frequently used worldwide in the treatment of major depressive disorder. There is a need for a thorough systematic review to provide the necessary background for weighing the benefits against the harms. This review will ultimately inform best practice in the treatment of major depressive disorder."

Journal • Retrospective data • Review • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry

Beneficial and harmful effects of antidepressants versus placebo, 'active placebo', or no intervention for adults with major depressive disorder: a protocol for a systematic review of published and unpublished data with meta-analyses and trial sequential analyses. (PubMed, Syst Rev) - "As antidepressants are commonly used to treat major depressive disorder in adults, a systematic review evaluating their beneficial and harmful effects is urgently needed. This review will inform best practice in treatment and clinical research of this highly prevalent and burdensome disorder."

Clinical • Journal • Review • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry • Suicidal Ideation

Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - P=N/A; N=100; Enrolling by invitation; Sponsor: Wroclaw Medical University; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Dec 2020 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Cardiovascular • CNS Disorders • Dental Disorders • Endocrine Disorders • Hypertension • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Chronic opipramol treatment extinguishes cocaine craving through Rac1 in responders: A rat model study. (PubMed, Addict Biol) - "We postulate that chronic activation of σ-1R, through a dynamic interaction with Rac1, may suggest a new approach to treat substance use disorder (SUD). Rac1 inhibition is a prerequisite for decreasing drug seeking and rehabilitation, and this can be achieved by opipramol, a medication that can be given during detoxification."

Journal • Preclinical • CNS Disorders • Depression • Mood Disorders • Psychiatry • RAC1

Consecutive Controlled Case Series on Effectiveness of Opipramol in Severe Sleep Bruxism Management-Preliminary Study on New Therapeutic Path. (PubMed, Brain Sci) - "A single 100 mg dose of opipramol at bedtime seems to positively affect the reduction of SB in otherwise healthy individuals diagnosed with severe SB. However, the subject requires further research on a larger population including a control group."

Clinical • Journal • Dental Disorders

Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - P=N/A; N=100; Enrolling by invitation; Sponsor: Wroclaw Medical University; Trial completion date: Sep 2020 ➔ Dec 2020; Trial primary completion date: Sep 2020 ➔ Dec 2020

Clinical • Trial completion date • Trial primary completion date • Cardiovascular • CNS Disorders • Dental Disorders • Endocrine Disorders • Hypertension • Obstructive Sleep Apnea • Sleep Apnea • Sleep Disorder

Interaction of sigma-1 receptor modulators with seizure development in pentylenetetrazole-induced kindled mice. (PubMed, Epilepsy Res) - "This study aimed to investigate the effects of sigma receptor modulators, opipramol and BD-1063, on epileptogenesis in pentylenetetrazole (PTZ)-kindling model of epilepsy. In contrast, the PTZ plus BD-1063 and the PTZ plus opipramol (5 mg/kg) plus BD-1063 group did not show full kindling. These findings indicate that opipramol has a pro-convulsant effect, which is possibly mediated through activation of sigma-1 receptors."

Journal • Preclinical • CNS Disorders • Epilepsy

Selected Disorders and Sleep Bruxism (clinicaltrials.gov) - P=N/A; N=100; Enrolling by invitation; Sponsor: Wroclaw Medical University; Trial completion date: May 2020 ➔ Sep 2020; Trial primary completion date: May 2020 ➔ Sep 2020

Clinical • Trial completion date • Trial primary completion date • Cardiovascular • CNS Disorders • Dental Disorders • Hypertension • Obstructive Sleep Apnea • Sleep Apnea • Sleep Disorder

Opipramol Inhibits Lipolysis in Human Adipocytes without Altering Glucose Uptake and Differently from Antipsychotic and Antidepressant Drugs with Adverse Effects on Body Weight Control. (PubMed, Pharmaceuticals (Basel)) - "The aim of the present study was to compare in human adipocytes the putative direct alterations of lipolysis by antipsychotics (haloperidol, olanzapine, ziprazidone, risperidone), antidepressants (pargyline, phenelzine), or anxiolytics (opipramol). Opipramol did not impair insulin activation of glucose transport but inhibited monoamine oxidase (MAO) activity to the same extent as antidepressants recognized as MAO inhibitors (pargyline, harmine, or phenelzine), whereas antipsychotics were inefficient. Considering its unique properties, opipramol, which is not associated with weight gain in treated patients, is a good candidate for drug repurposing because it limits exaggerated lipolysis, prevents hydrogen peroxide release by amine oxidases in adipocytes, and is thereby of potential use to limit lipotoxicity and oxidative stress, two deleterious complications of diabetes and obesity."

Adverse events • Journal

Antidepressants and the risk of death in older patients with depression: A population-based cohort study. (PubMed, PLoS One) - "This study suggests that ADs recommended as first-line treatment in patients with depression have a similar safety profile with regard to the risk of death, especially in very old patients and in those with dementia. Further research is needed to investigate the risk of death for individual ADs in specific subgroups such as patients with cancer or cardiovascular disease."

Clinical • Journal

The Dopamine Receptor Antagonism of Opipramol: Relevance to Parkinsonism? (PubMed, Clin Neuropharmacol) - "This frequently prescribed anxiolytic drug has so far not been associated with DIP. Our objective is to raise awareness of DIP as an adverse effect of opipramol."

Journal

Antidepressants and the risk of traumatic brain injury in the elderly: differences between individual agents. (PubMed, Clin Epidemiol) - "...Compared with remote users of the same AD, current users had an aOR (95% CI) of 1.87 (1.56-2.24) for duloxetine, 1.74 (1.41-2.15) for escitalopram, 1.70 (1.58-1.83) for citalopram, 1.66 (1.40-1.97) for sertraline, 1.64 (1.24-2.15) for fluoxetine and 1.57 (1.20-2.06) for paroxetine. The aOR was lower for amitriptyline (1.45; 1.32-1.58), trimipramine (1.17; 0.99-1.38) and opipramol (1.11; 0.99-1.25). Mirtazapine had an aOR of 1.03 (0.94-1.12). Sensitivity analysis confirmed the findings. The large variability between individual ADs shows the importance of considering the safety of individual agents rather than focusing on class alone."

Clinical • Journal